Skip to main content

Spain Warned Economy at Risk as New Virus Restrictions Planned

By Unknown

Spain’s nascent economic recovery is under threat because of a second wave of coronavirus infections, the International Monetary Fund said, warning that the government shouldn’t remove fiscal support too early.

Spain has the highest number of cases in Europe, and the IMF assessment comes as the country prepares to impose new targeted restrictions in hotspots such as Madrid. Health officials from regional administrations will on Wednesday be asked to approve government plans, which would involve additional curbs on social gatherings as well as bars and restaurants.

While such measures will hit the already-beleaguered hospitality industry, the IMF said controlling the virus is vital for the economy. In the review, which was conducted before the latest measures were announced, it predicted a 12.8% economic contraction this year.

“Getting the second wave of infections under control will be critical for the economic outlook,” the Washington-based fund said. Risks are “tilted strongly to the downside.”

Madrid has become the focus of the pandemic in Europe after the number of new cases surged toward the end of the peak tourist season and a fight between local and national leaders delayed the introduction of new measures.

But the dilemma over how to restrict movement without completely undermining the economy is also playing out across Europe, where the rate of infections has accelerated. In recent days, Germany, France and Italy all posted the highest figures since they eased lockdowns before the summer.

Spain is particularly vulnerable to the pandemic crisis because of its reliance on tourism and its greater concentration of small companies, many of which don’t have the financial strength to cope with even a short-term disruption.

Also, companies rely heavily on precarious, temporary contracts -- a long-standing flaw that means unemployment could rise to around 20% this year and hover around that level for at least a couple of years.

For that reason, the IMF said the government should maintain its national furlough program as well as a state-backed loan guarantee fund, making them more targeted as the crisis drags on. It should also consider extending some version of a temporary equity support fund for large companies to some viable smaller firms.

More than 30,000 people in Spain have been killed by Covid-19 since the start of the outbreak and the country has been adding almost 50,000 new cases a week.


Comments

Post a Comment

Popular posts from this blog

Increased risks of drop out for women and girls : CoronaVirus Updates

By Unknown
The total number of children not returning to their education after the school closures is likely to be significant. The pandemic also risks jeopardizing some of the gains made since 2001 in re-building women and girls’ education following the Taliban regime.  The COVID-19 pandemic is creating additional barriers due to risks—and students’ and parents’ anxiety about risks—associated with children returning to classrooms that are cramped, with no capacity for distancing, often cold, damp and poorly ventilated during the country’s severe winters, and have no or poor hygiene and clean water facilities. The COVID-19 pandemic is likely to drive many women and girls out of education permanently. School closures due to COVID-19, resulting increases in caregiving responsibilities for women and girls, and increases in poverty and unemployment will all make it harder for women and girls to study.  These factors combine in harmful ways with pre-existing discriminatory gender norms, o...
Post a Comment
Read more

Glenmark's antiviral combination for moderate Covid-19 shows no clinical benefit

By Unknown
Glenmark Pharmaceuticals Ltd on Friday said addition of Umifenovir did not demonstrate any additional benefit over Favipiravir alone in moderate Covid-19 patients. Umifenovir did not show superior clinical outcomes when added to Favipiravir treatment, the trial did not meet key end-points,  the company said. The trial's findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes, Monika Tandon, senior vice president & head, Clinical Development, Global Specialty/Branded Portfolio at the company, said in a statement , adding that favipiravir alone remains the effective choice for mild to moderate COVID-19 infection. Favipiravir is made under the brand name Avigan by Japan's Fujifilm Holdings Corp and was approved for use as an anti-flu drug there in 2014, while Umifenovir is licensed as a treatment for some types of flu infections in Russia and China. Fujifilm last month said a late-stage study of Avigan showed i...
Post a Comment
Read more

No significant benefit of Umifenovir in COVID-19 treatment: Glenmark

By Unknown
Drug firm  Glenmark Pharmaceuticals  on Friday said the addition of  antiviral Umifenovir  did not demonstrate any significant clinical benefit over  Favipiravir  alone in  moderate COVID-19 patients .  The  clinical study  evaluated the possible superiority of the combination's efficacy against Favipiravir monotherapy, Glenmark said in a statement. As per the results that Glenmark presented to the regulator, the study showed no superior clinical outcomes with the addition of Umifenovir, it added. This was the second clinical study after the successful Favipiravir monotherapy trial earlier this year that led the company to receiving the Emergency Use Authorisation for Favipiravir, Glenmark said. "These latest findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes. Thus Favipiravir therapy along with supportive care remains a suitable and effective choice for mild to moderate COVID-1...
Post a Comment
Read more